FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 & TB 500 Blend 10mg 10mg Peptide Tech Peptides got reclassified the moment they started threatening real revenue. Not because new safety data emerged. Not because patients started getting hurt. The moment pharma noticed people were healing tendons, sleeping better, FDA to Convene Pharmacy Compounding Advisory Committee in July